
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is a promising biopharmaceutical company with innovative RNA-editing technology, particularly the potential of its lead candidate, KRRO-121, to treat urea cycle disorders (UCDs) and other diseases. Its recently completed PIPE financing has provided the company with a strong balance sheet and extended operational runway, reducing near-term financial risks. However, delays or failures in clinical trials, particularly with KRRO-121, and future dilution concerns are potential risks for investors to consider.
Bears say
Korro Bio is heavily reliant on its AATD program for revenue, as seen through the lack of significant current or projected income. While their advancements in ASGCT data is noteworthy, Korro's dependence on a single main program poses a high level of risk to investors. This is compounded by the fact that the AATD program is still in early stages, with key decisions and filings not expected until at least 2026.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares